ADN-MCL is a preclinical personalized vaccine product candidate in discovery phase for Mantle Cell Lymphoma (MCL), an aggressive, rare and fatal lymphoma predominantly diagnosed in male patients over 50 years old. MCL is a long-term debilitating and life-threatening disease associated with poor overall survival.
Prognosis of advanced stage MCL is poor with conventional chemotherapy, as although it improves the response rate (about 30%), it does not improve progression-free survival or overall survival. Therefore, there is a strong medical need for an immunotherapeutic approach that will deliver a more lasting therapeutic benefit.
ADIENNE is developing a proprietary technological solution that is expected to allow the timely generation of such a personalized MCL vaccine aimed to increase progression free and overall survival for MCL patients in a meaningful time frame and at commercially feasible conditions.